Research area · week to 3 Oct 2026

Retinal Diseases and Treatments

Moving in Frontiers in Genetics, Nature Communications.

Moved this week: 2

Rebuilt 3 October 2026 at 2:43 pm AEST

Moved this week

Everything that moved →

MYDGF promotes pathological and physiological retinal angiogenesis via the Gαi1/3-Gab1-Akt-mTOR signaling.
Nature Communications · 23 June 2026 · Journal Article
MYDGF drives retinal angiogenesis through Gαi1/3-Gab1-Akt-mTOR signaling, promoting both pathological and physiological vessel growth in mice and humans.
- 1 opens in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42336863
Open in JClub
Preclinical evaluation of AL-001, a gene therapy for wet age-related macular degeneration.
Frontiers in Genetics · 1 Sept 2026 · Journal Article
Suprachoroidal delivery of AL-001 achieves sustained aflibercept expression and superior efficacy with minimal inflammation in a nonhuman primate model of wet age-related macular degeneration.
- 1 opens in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42745920
Open in JClub

Latest in Retinal Diseases and Treatments

Newest first · last 60 days

VCP inhibition prevents cone photoreceptor degeneration in the cpfl1 mouse model of achromatopsia
bioRxiv · 26 Sept 2026 · Preprint
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.09.21.753131
Open in JClub
Transducin: an open-source pipeline recovering SNOMED-CT coded measurements from the undocumented Optopol .OPT and Zeiss Cirrus private-tag formats as DICOM Structured Reports
medRxiv · 25 Sept 2026 · Preprint
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.07.14.26357256
Open in JClub
A Single Suprachoroidal Injection of AXT107 (Gersizangitide), a Multimodal, Long-Acting Integrin-Disrupting Peptide, in Patients with Neovascular Age-Related Macular Degeneration: Results of the Phase 1/2a DISCOVER Trial
medRxiv · 24 Sept 2026 · Preprint
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.09.19.26363031
Open in JClub
Variant-to-gene mapping in ocular cell types identifies candidate effector genes for primary open-angle glaucoma
bioRxiv · 14 Sept 2026 · Preprint
Read the brief in JClub
- Open access
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.02.20.707051
Open in JClub
Preclinical evaluation of AL-001, a gene therapy for wet age-related macular degeneration.
Frontiers in Genetics · 1 Sept 2026 · Journal Article
Suprachoroidal delivery of AL-001 achieves sustained aflibercept expression and superior efficacy with minimal inflammation in a nonhuman primate model of wet age-related macular degeneration.
- 1 opens in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42745920
Open in JClub
Revisiting retinal and macular degeneration in the genomics era.
Nature Reviews Genetics · 1 Sept 2026 · Review
Genomic advances have identified causal genes and variants, paving the way for targeted therapies for retinal and macular degeneration affecting millions globally.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42230802
Open in JClub
Glucagon-like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy : A Target Trial Emulation.
Annals of Internal Medicine · 1 Sept 2026 · Observational Study
Glucagon-like peptide-1 receptor agonists increase the 18-month risk of ischemic optic neuropathy by approximately 3 to 3.6 cases per 10,000 patients compared to other diabetes medications.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42441967
Open in JClub
Axial Length Matters: Scaling Effects in Retinal Fundus Image Analysis
medRxiv · 21 Aug 2026 · Preprint
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.03.03.26347501
Open in JClub
Biologically Driven In Vivo Occlusion Design Provides a Reliable Experimental Glaucoma Mouse Model
bioRxiv · 21 Aug 2026 · Preprint
Viscobeads induce sustained ocular hypertension of 21.4 mm Hg for at least 8 weeks in mice, causing significant retinal ganglion cell loss and visual impairment.
- Open access
- 4 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.1101/2024.01.18.576306
Open in JClub

Follow this area in the app

Journals this month

All journals →

Moving areas, week to 3 Oct 2026

All research areas →

Read

Moved this week

Latest in Retinal Diseases and Treatments

Browse JClub